Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis

被引：0
|
作者：
Jeroen P. Jansen
Sabine Gaugris
Ernest H. Choy
Andrew Ostor
Julian T. Nash
Wiro Stam
机构：
[1] Mapi Values,Sir Alfred Baring Garrod Clinical Trials Unit, Academic Department of Rheumatology
[2] Outcome Research,Department of Rheumatology
[3] Merck & Co.,Department of Rheumatology, Royal National Orthopaedic Hospital
[4] Inc.,undefined
[5] GKT School of Medicine,undefined
[6] King’s College Hospital,undefined
[7] Addenbrooke’s Hospital,undefined
[8] Stanmore Hospital,undefined
[9] Mapi Values,undefined
来源：
PharmacoEconomics | 2010年 / 28卷
关键词：
Ankylose Spondylitis; Celecoxib; Naproxen; Etoricoxib; Bath Ankylose Spondylitis Disease Activity Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To evaluate the cost effectiveness of etoricoxib (90mg/day) relative to celecoxib (200 or 400mg/day), and the non-selective NSAIDs naproxen (1000mg/day) and diclofenac (150 mg/day) in the initial treatment of ankylosing spondylitis (AS) from the UK NHS perspective.
引用
收藏
页码：323 / 344
页数：21
相关论文
共 50 条
  • [1] Cost Effectiveness of Etoricoxib versus Celecoxib and Non-Selective NSAIDS in the Treatment of Ankylosing Spondylitis
    Jansen, Jeroen P.
    Gaugris, Sabine
    Choy, Ernest H.
    Ostor, Andrew
    Nash, Julian T.
    Stam, Wiro
    PHARMACOECONOMICS, 2010, 28 (04) : 323 - 344
  • [2] Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK
    Jansen, JP
    Hunsche, E
    Choy, E
    Ostor, A
    Nash, JT
    Bacon, P
    Pellissier, J
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 400 - 400
  • [3] Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK
    Jansen, Jeroen P.
    Pellissier, James
    Choy, Ernest H.
    Ostor, Andrew
    Nash, Julian T.
    Bacon, Paul
    Hunsche, Elke
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 3069 - 3078
  • [4] Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway
    Jansen, Jeroen P.
    Taylor, Stephanie D.
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011
  • [5] Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of ankylosing spondylitis in the UK.
    Jansen, JP
    Hunsche, E
    Choy, E
    Oster, A
    Pellissier, J
    Values, M
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S397 - S397
  • [6] Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK
    Eduardo Carracedo-Martínez
    PharmacoEconomics, 2005, 23 : 743 - 743
  • [7] Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK
    Carracedo-Martínez, E
    PHARMACOECONOMICS, 2005, 23 (07) : 743 - 743
  • [8] Economic Evaluation of Etoricoxib versus Non-Selective NSAIDs in the Treatment of Osteoarthritis and Rheumatoid Arthritis Patients in the UK
    Andrew Moore
    Ceri Phillips
    Elke Hunsche
    James Pellissier
    Simone Crespi
    PharmacoEconomics, 2004, 22 : 643 - 660
  • [9] Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK
    Moore, A
    Phillips, C
    Hunsche, E
    Pellissier, J
    Crespi, S
    PHARMACOECONOMICS, 2004, 22 (10) : 643 - 660
  • [10] Etoricoxib and the treatment of ankylosing spondylitis
    Lories, Rik J.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2012, 8 (12) : 1599 - 1608
12345